Post-doctoral position available at INSERM UMR_S999
« Pulmonary Hypertension: Pathophysiology and Novel Therapies » laboratory

Job Description: The team "***Endothelial dysfunction & Cell miscommunication***" is located at Paris-Saclay University, within the INSERM U999 unit headed by Pr Marc Humbert, whose research is dedicated to the pathophysiology of pulmonary hypertension. The team focuses on a better understanding of the role played by pulmonary endothelial dysfunction associated to pulmonary arterial hypertension, a key pathogenetic mechanism detrimental for disease susceptibility and development of pulmonary vascular remodeling. We investigate the mechanisms by which pulmonary endothelial cells interact with their environment, with both resident vascular cells (smooth muscle cells, myofibroblasts and pericytes) and circulating cells (inflammatory and immune cells).

We are welcoming experienced, highly motivated and autonomous post-doctoral research scientists. The candidate will develop and carry on his own research projects aiming at deciphering **mechanisms of immune dysregulation in pulmonary hypertension** under the guidance of Drs Alice Huertas, Ly Tu, and Christophe Guignabert. The post-doc will also develop new approaches and tools. The candidate will also participate and add his expertise in other members' projects.

Requirements: The candidate should have an interest in translational research and be able to work independently and interactively in a team setting, be responsible, organized and have a great work capacity and enthusiasm for research.
PhD (or equivalent) in immunology and immunopathology is required and the applicant should have a strong expertise in immunobiology and pathogenesis of immunological disorders. Experience in bioinformatics would be a plus.

Research field: Pulmonary hypertension describes a group of devastating diseases, comprising idiopathic and associated forms, causing breathlessness, loss of exercise capacity and death due to elevated pulmonary artery pressure and subsequent right heart failure. Extensive pulmonary artery remodeling with loss of vessel patency is the underlying pathomechanism. On the basis of a nationwide web-based Registry, a biobank, and highly competitive scientists, our group is studying a number of molecular pathways causing pulmonary vascular remodeling in human and animal models of pulmonary hypertension, identify targets for therapy, fostering drug development based on these targets and test novel treatments.
The main scope of the Research Team "*Pulmonary hypertension: Pathophysiology and novel therapies*" relates to pathophysiology and clinical management by deciphering the mechanisms of lung vascular remodeling and identifying novel molecular targets, in order to alleviate and cure pulmonary hypertension.

Starting date: The position is available early 2021.

Contacts:
Dr Christophe GUIGNABERT (christophe.guignabert@inserm.fr)
Dr Alice HUERTAS (alice.huertas@inserm.fr)
Website : http://www.u999.universite-paris-saclay.fr/en/
UMR_S 999 « Pulmonary Hypertension: Pathophysiology and Novel Therapies «
Director: Pr Marc HUMBERT
Address: Hôpital Marie Lannelongue, 133 Avenue de la résistance, 92350 Le Plessis-Robinson, France